ATE368447T1 - Verwendung eines assoziates aus synergistischen kalziumkanalblocker-agentien zur vermeidung oder behandlung von falten und feinen linien - Google Patents

Verwendung eines assoziates aus synergistischen kalziumkanalblocker-agentien zur vermeidung oder behandlung von falten und feinen linien

Info

Publication number
ATE368447T1
ATE368447T1 AT03292767T AT03292767T ATE368447T1 AT E368447 T1 ATE368447 T1 AT E368447T1 AT 03292767 T AT03292767 T AT 03292767T AT 03292767 T AT03292767 T AT 03292767T AT E368447 T1 ATE368447 T1 AT E368447T1
Authority
AT
Austria
Prior art keywords
calcium channel
association
prevent
blocking agents
fine lines
Prior art date
Application number
AT03292767T
Other languages
English (en)
Inventor
Beatrice Renault
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of ATE368447T1 publication Critical patent/ATE368447T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23Sulfur; Selenium; Tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Wrappers (AREA)
  • Packages (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT03292767T 2002-11-13 2003-11-05 Verwendung eines assoziates aus synergistischen kalziumkanalblocker-agentien zur vermeidung oder behandlung von falten und feinen linien ATE368447T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214183A FR2846885B1 (fr) 2002-11-13 2002-11-13 Utilisation d'une association de composants a effet synergique inhibiteur de canaux calciques pour prevenir ou traiter les ridules

Publications (1)

Publication Number Publication Date
ATE368447T1 true ATE368447T1 (de) 2007-08-15

Family

ID=32116584

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03292767T ATE368447T1 (de) 2002-11-13 2003-11-05 Verwendung eines assoziates aus synergistischen kalziumkanalblocker-agentien zur vermeidung oder behandlung von falten und feinen linien

Country Status (6)

Country Link
EP (1) EP1419764B1 (de)
JP (1) JP2004161773A (de)
AT (1) ATE368447T1 (de)
DE (1) DE60315238T2 (de)
ES (1) ES2290413T3 (de)
FR (1) FR2846885B1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004323400A (ja) * 2003-04-23 2004-11-18 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
US20050118124A1 (en) * 2003-12-01 2005-06-02 Reinhart Gale M. Compositions for treating keratinous surfaces
DE102004007385A1 (de) * 2004-02-11 2005-09-01 Coty B.V. Antifalten-Kosmetikum
FR2866810B1 (fr) * 2004-03-01 2006-04-28 Oreal Utilisation d'au moins un inhibiteur des canaux calciques pour prevenir et/ou traiter la peau grasse.
FR2872416B1 (fr) * 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
JP2008536797A (ja) * 2004-12-29 2008-09-11 ラボ コスプロファー アクチェンゲゼルシャフト 表情皺を緩和するのに好適な皮膚投与のための美容組成物
JP2008531725A (ja) * 2005-03-03 2008-08-14 ルバンス セラピュティックス インク. オリゴペプチドの局所適用及び経皮送達のための組成物及び方法
ES2259928B1 (es) * 2005-04-08 2007-11-01 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
JP4972088B2 (ja) * 2005-06-06 2012-07-11 イーエルシー マネージメント エルエルシー 局所オリゴペプチド送達システム
JP2011207769A (ja) * 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
US20110305735A1 (en) 2010-06-09 2011-12-15 Lipotec, S.A. Skin antiaging treatment
RU2524428C1 (ru) * 2013-01-21 2014-07-27 Общество с ограниченной ответственностью "Синейро" Пептиды и их производные, взаимодействующие с никотиновым ацетилхолиновым рецептором и пригодные для использования в косметологии против мимических и возрастных морщин
JP6784442B2 (ja) * 2015-04-13 2020-11-11 エルジー ハウスホールド アンド ヘルスケア リミテッド 神経伝達物質の排出を調節する成分が含まれた溶解性マイクロニドル

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434220T2 (de) * 1993-05-14 2005-12-22 Arnon, Stephen S., Orinda Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
FR2793681B1 (fr) * 1999-05-18 2001-06-22 Oreal Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides
FR2798590B1 (fr) * 1999-09-21 2001-11-30 Oreal Utilisation de l'alverine pour diminuer les rides
FR2826267B1 (fr) * 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un agent myorelaxant

Also Published As

Publication number Publication date
FR2846885A1 (fr) 2004-05-14
EP1419764B1 (de) 2007-08-01
FR2846885B1 (fr) 2004-12-24
EP1419764A1 (de) 2004-05-19
DE60315238D1 (de) 2007-09-13
JP2004161773A (ja) 2004-06-10
DE60315238T2 (de) 2008-04-17
ES2290413T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
ATE368447T1 (de) Verwendung eines assoziates aus synergistischen kalziumkanalblocker-agentien zur vermeidung oder behandlung von falten und feinen linien
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE60335997D1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
DE69232629D1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
BG102619A (en) Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propylamides
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE59410358D1 (de) Verwendung von carnosin in kombination mit urocaninsäure zur behandlung von photodermatosen
ATE440612T1 (de) Verwendung von hülsenfrüchten zur herstellung von produkten zum schutz oder behandlung von radiotherapie-bedingten hautschäden
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
ATE225125T1 (de) Lösung zur konservierung von organen oder geweben oder teilen davon aus menschen oder tieren
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE486612T1 (de) Verfahren zur behandlung von diabetes typ 2
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
DE69402826T2 (de) Zusammensetzung zur haarpflege
BR0212373A (pt) Processos e composições para o tratamento de artigos de couro e artigos de couro assim tratado
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60123833D1 (de) Entwurf und verwendung von verbesserten zink-chelatbildenden peptiden zur regulation von matrix-metalloproteinasen
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE406868T1 (de) Verwendung einer zusammensetzung mit vitamin k1- oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
DE60318423D1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties